Wang T, Wang S, Li Z, Xie J, Jia Q, Hou J
Cancer Cell Int. 2025; 25(1):43.
PMID: 39948551
PMC: 11827143.
DOI: 10.1186/s12935-025-03651-y.
Wu Q, Fu X, Liu G, He X, Li Y, Ou C
J Hematol Oncol. 2025; 18(1):12.
PMID: 39881381
PMC: 11780989.
DOI: 10.1186/s13045-025-01665-7.
Zhou W, Yi Y, Cao W, Zhong X, Chen L
Front Pharmacol. 2025; 15():1491763.
PMID: 39850560
PMC: 11754259.
DOI: 10.3389/fphar.2024.1491763.
Wu H, Chen S, Li X, Li Y, Shi H, Qing Y
MedComm (2020). 2025; 6(1):e70042.
PMID: 39802639
PMC: 11718328.
DOI: 10.1002/mco2.70042.
Zheng Y, Li H, Lin S
Front Genet. 2024; 15:1469011.
PMID: 39262420
PMC: 11387174.
DOI: 10.3389/fgene.2024.1469011.
Targeting treatment resistance: unveiling the potential of RNA methylation regulators and TG-101,209 in pan-cancer neoadjuvant therapy.
Zhou Y, Liu Z, Gong C, Zhang J, Zhao J, Zhang X
J Exp Clin Cancer Res. 2024; 43(1):232.
PMID: 39160604
PMC: 11331809.
DOI: 10.1186/s13046-024-03111-x.
Neuroblastoma susceptibility and association of N7-methylguanosine modification gene polymorphisms: multi-center case-control study.
Lin H, Liao F, Liu J, Yang Z, Zhang J, Cheng J
Pediatr Res. 2024; 97(1):153-159.
PMID: 38871802
DOI: 10.1038/s41390-024-03318-w.
RNA methylation-related inhibitors: Biological basis and therapeutic potential for cancer therapy.
Chen H, Liu H, Zhang C, Xiao N, Li Y, Zhao X
Clin Transl Med. 2024; 14(4):e1644.
PMID: 38572667
PMC: 10993167.
DOI: 10.1002/ctm2.1644.
M7G-related tumor immunity: novel insights of RNA modification and potential therapeutic targets.
Han M, Huang Q, Li X, Chen X, Zhu H, Pan Y
Int J Biol Sci. 2024; 20(4):1238-1255.
PMID: 38385078
PMC: 10878144.
DOI: 10.7150/ijbs.90382.
Genetic variants of m7G modification genes influence neuroblastoma susceptibility.
Liu J, Deng C, Lin H, Zhang X, Zhu J, Zhou C
Heliyon. 2024; 10(1):e23658.
PMID: 38173492
PMC: 10761801.
DOI: 10.1016/j.heliyon.2023.e23658.
Establishment of a new molecular subtyping and prognostic signature with m6A/m5C/m1A/m7G regulatory genes for hepatocellular carcinoma.
Liu T, Wang Y, Li Z, Sun L, Yang K, Chen J
Heliyon. 2023; 9(11):e21285.
PMID: 38027812
PMC: 10660009.
DOI: 10.1016/j.heliyon.2023.e21285.
The mG Reader NCBP2 Promotes Pancreatic Cancer Progression by Upregulating MAPK/ERK Signaling.
Xie J, Mo T, Li R, Zhang H, Liang G, Ma T
Cancers (Basel). 2023; 15(22).
PMID: 38001714
PMC: 10670634.
DOI: 10.3390/cancers15225454.
Epitranscriptomic modifications in mesenchymal stem cell differentiation: advances, mechanistic insights, and beyond.
Zheng J, Lu Y, Lin Y, Si S, Guo B, Zhao X
Cell Death Differ. 2023; 31(1):9-27.
PMID: 37985811
PMC: 10782030.
DOI: 10.1038/s41418-023-01238-6.
Insights into the regulatory role of RNA methylation modifications in glioma.
Long S, Yan Y, Xu H, Wang L, Jiang J, Xu Z
J Transl Med. 2023; 21(1):810.
PMID: 37964279
PMC: 10644640.
DOI: 10.1186/s12967-023-04653-y.
Evaluation of the serum tRNA-derived fragment tRF-5022B as a potential biomarker for the diagnosis of osteoarthritis.
Ni Y, Wu A, Li J, Zhang W, Wang Y
J Orthop Surg Res. 2023; 18(1):800.
PMID: 37880787
PMC: 10601305.
DOI: 10.1186/s13018-023-04273-8.
Biological roles of RNA m7G modification and its implications in cancer.
Zhang X, Zhu W, Shen S, Shen J, Chen X
Biol Direct. 2023; 18(1):58.
PMID: 37710294
PMC: 10500781.
DOI: 10.1186/s13062-023-00414-5.
Establishment of a prognostic model toward lung squamous cell carcinoma based on mG-related genes in the cancer genome atlas.
Wang Y, Liu Y, Wang R, Cao F, Guan Y, Chen Y
Physiol Genomics. 2023; 55(10):427-439.
PMID: 37575065
PMC: 10642926.
DOI: 10.1152/physiolgenomics.00149.2022.
M7G methylated core genes (METTL1 and WDR4) and associated RNA risk signatures are associated with prognosis and immune escape in HCC.
Li R, Liu X, Deng K, Wang X
BMC Med Genomics. 2023; 16(1):179.
PMID: 37528384
PMC: 10394781.
DOI: 10.1186/s12920-023-01614-8.
N7-methylguanosine modification: from regulatory roles to therapeutic implications in cancer.
Cai M, Yang C, Wang Z
Am J Cancer Res. 2023; 13(5):1640-1655.
PMID: 37293166
PMC: 10244098.
gene polymorphisms and Wilms tumor susceptibility in Chinese children: A five-center case-control study.
Deng L, Hua R, Deng C, Zhu J, Zhang Z, Cheng J
J Cancer. 2023; 14(8):1293-1300.
PMID: 37283791
PMC: 10240673.
DOI: 10.7150/jca.83747.